Abstract Body

Background: Safe and effective pediatric antiretroviral therapies are needed. Elvitegravir (EVG) is a once-daily integrase inhibitor in regulatory review for treatment of HIV-1 infection when coadministered with a pharmacoenhancer. This study evaluated the pharmacokinetics (PK) of ritonavir (RTV)-boosted EVG administered as the pediatric EVG tablet or suspension formulation (test) vs the adult EVG 150 mg tablet formulation (reference). Methodology: This was a prospective, open-label, crossover, randomized, multiple cohort study in healthy adult subjects. Cohort 1 (n=30) evaluated the single dose PK of the pediatric tablets (3 X 50 mg) vs reference. Cohort 2 (n=26) evaluated the single dose PK of the pediatric suspension (30 mL; 5 mg/mL) vs reference. Cohort 3 (n=18) evaluated the multiple dose PK of both pediatric formulations. . All treatments included 100 mg of RTV as a pharmacoenhancer and were administered under fed conditions with 240 mL of water. Intensive PK sampling was conducted over 48 hours post dose and PK parameters were calculated using noncompartmental methods. BE was assessed in Cohorts 1 and 2 using geometric mean ratios (GMR) and associated 90% confidence interval (CI) bounds of 80%-125% (>85% power to conclude BE). In Cohort 3, only descriptive PK was assessed. Safety assessments were performed throughout study and during follow-up. Results: Study treatments were generally well tolerated. All enrolled subjects (n=74) completed the study. No Grade 2, 3 or 4 adverse events were observed. Mean (%CV) and the GMR (90%CI) of EVG PK parameters are presented in Table 1. In Cohorts 1 and 2, EVG exposure (AUClast, AUCinf, and Cmax) were within the protocol-defined BE bounds for both the pediatric tablet and suspension formulations vs the reference (adult) tablet formulation. In Cohort 3, EVG PK following multiple doses of EVG with RTV was comparable between pediatric tablet and suspension formulations and consistent with historical steady state data of boosted EVG, including achievement of mean trough concentrations (EVG Ctau) ~8.5 and 9.2-fold, respectively, above the IC95 (44.5 ng/mL). Conclusions: EVG pediatric tablet and suspension formulations were each bioequivalent to adult tablets, when coadministered with RTV. The EVG formulations were well tolerated, and the multiple dose PK of both formulations were consistent with historical data of boosted EVG. As such, these study findings support evaluation of these pediatric formulations in HIV infected children.